Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
| Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
| Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 11, 2024